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Background: The long term complications of diabetes can be fatal. They are also renowned for 
being an economic burden. Previous studies have demonstrated a relationship between inflam-
matory markers and complications of diabetes. The objective of this study was to evaluate the 
relationship between leukocyte counts and these complications.
Methods: The study included 184 patients diagnosed with type 2 diabetes. The study was carried 
out in Iran during 2007 and 2008. Data collected on the subjects were as follows: age, gender, 
weight, height, blood pressure, smoking history, lipid profile including low density lipoprotein 
(LDL), high density lipoprotein (HDL), total cholesterol, triglycerides, and leukocyte count, 
albuminuria, and retinopathy. Furthermore, information on cardiac history for 100 patients 
was collected. The subjects were split into two groups according to their   leukocyte levels: low 
(#7000/mm³) and high (.7000/mm³); and then analyzed by Student’s t-test or Mann–Whitney 
U-test as appropriate.
Results: The average leukocyte count in these patients was 7594 ± 1965/mm³. Leukocyte count 
was significantly different in patients with and without retinopathy and albuminuria (P , 0.0001). 
According to this analysis, a leukocyte count of 6750/mm³ with a sensitivity of 80.2% and a 
specificity of 56.4%, and a count of 7550/mm³ with a sensitivity of 63.2% and a specificity of 
74.6% indicated at least one diabetes complication.
Conclusion: An elevated leukocyte count even within the normal range was associated with 
chronic complications in type 2 diabetes.
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Introduction
Type 2 diabetes mellitus is a chronic illness that requires appropriate medical care and 
patient education in a self-management program to reduce long term complications.1 It 
is characterized by hyperglycemia and other metabolic disorders resulting from insulin 
resistance that is responsible for pathophysiologic changes in various body organs.2 
It is estimated that there will be about 300 million individuals fighting diabetes by 
the year 2025 and, according to World Health Organization statistics, each diabetic 
patient spends about three times more money on his or her health than a person without 
diabetes.3 The long term complications that result from poor glycemic control contribute 
substantially to the morbidity, mortality, and economic burden of diabetes.4
Diabetes is the main cause of blindness and end stage renal disease in adults.5–7 
Furthermore, most evidence indicates that atherosclerosis progresses faster in diabetic 
patients than in people without diabetes.8 Some investigations show that lowering the 
serum glucose level will delay the occurrence of complications.9,10
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There are some conventional and important risk factors 
that affect the development of complications of diabetes, but 
they cannot fully explain this excess risk. In recent studies the 
focus was on inflammatory factors. These studies determined 
that higher C-reactive protein, fibrinogen, and leukocyte 
count were related to higher risk of cardiac events.11–13 It was 
shown that leukocytes play an important role in the progres-
sion of diabetes complications.14 Leukocytes can be activated 
by glycation end products, oxidative stress, angiotensin II 
resulting from hyperglycemia, and can produce factors like 
tumor necrosis factor-α and interleukin β1 that involve 
chronic diabetes complication pathogenesis.15–19
Thus, early diagnosis and treatment of diabetes can prevent 
or reduce the development of complications. Furthermore, 
we need cost benefit and in reach methods to identify 
those patients who need more care. Therefore, this study 
was carried out to investigate the association of leukocyte 
count as a biomarker for inflammation with microvascular 
and macrovascular complications in diabetic individuals. 
Leukocyte count is a cost effective and available laboratory 
test that can show inflammatory activity.
Material and methods
Patients diagnosed with type 2 diabetes in Iran during the 
years 2007 and 2008 (n = 184) were included in our analytical 
cross sectional study. All diagnoses were based on   American 
Diabetes Association diagnostic criteria.20 All patients’ 
files including age, gender, weight, height, blood pressure, 
  smoking history, lipid profile including low density lipopro-
tein (LDL), high density lipoprotein (HDL), total cholesterol, 
and triglycerides, and leukocyte count, albuminuria, and 
retinopathy were made available. Furthermore, information 
on cardiac histories was collected for 100 of the patients. 
Patients with any kind of malignancy, infection in the past 
2 weeks, or chronic inflammatory diseases such as rheuma-
toid arthritis in their medical history were excluded.
All Biochemical assays were carried out in the Institute 
of Endocrinology and Metabolism Laboratory, Tehran, Iran. 
Total cholesterol, HDL, and triglycerides were measured 
by photometric assay. Intra- and inter-assay coefficients of 
variation for all tests were less than 2% (Teif Azmoon Pars 
Co, Tehran, Iran), and LDL was calculated with the use of 
Friedwald formula.
Albuminuria was diagnosed from a 24-hour urine collection 
albumin measurement. Albuminuria was defined based on 
urinary albumin excretion more than 30 mg/24 h. Retinopathy 
was detected and differentiated by an ophthalmologist by 
funduscopy and was defined based on nonproliferative and 
proliferative retinopathies. Cardiac events were filed by the 
opinion of a cardiologist, electrocardiogram or history of 
coronary care unit admission at least 2 years after diagnosis 
of diabetes.
Statistical analysis
All data were analyzed by SPSS software for Windows 
(v16.0; SPSS, Chicago, IL). Data were first evaluated for log 
normal distribution by Kolmogorov-Smirnov test and were 
described with mean ± standard deviation. Leukocyte count 
results were split into two groups as follows: low (#7000/
mm³) and high (.7000/mm³), and then analyzed by Stu-
dent’s t-test or Mann–Whitney U-test as appropriate. Other 
statistical tests such as correlation and logistic regression 
were used when appropriate. For finding the best cutoff point 
for leukocyte counts to evaluate the complications, receiver 
operating characteristic analysis was performed. P value less 
than 0.05 was considered significant.
Ethical issues
All patients were informed and signed consent was obtained 
from patients or from their next of kin prior to the study. 
The subject’s medical information was kept secret during 
the analysis and all participated as anonymous. The study 
protocol was evaluated and approved by Tehran University 
of Medical Sciences Institutional review board.
Results
In this analytical, cross sectional study, there were 64 (34.8%) 
male and 120 (68.2%) female subjects. The patients’ mean 
age was 55.08 ± 11.8 years, and their duration of diabetes 
from the time of diagnosis was 9.7 ± 7.3 years. Average 
  leukocyte count in these patients was 7594 ± 1965/mm³. 
Other baseline characteristics are shown in Table 1.
Before using our cutoff point, analyses were done using 
pure leukocyte count. There was no significant   correlation 
between leukocyte count with serum total cholesterol (R = 0.01, 
P = 0.8), triglyceride levels (R = 0.07, P = 0.3), and a patient’s 
body mass index (BMI) (R = 0.50, P = 0.5). Linear regression 
model showed that leukocyte count could predict the number of 
complications in diabetic individuals (R² = 0.55, P , 0.001).
Leukocyte counts had significant difference in patients 
with and without retinopathy and albuminuria (P , 0.0001). 
Furthermore, the subjects were divided into two groups 
according to any kind of complication and we found a sig-
nificant difference in leukocyte counts within these groups 
(P , 0.0001). Receiver operating characteristic analysis was 
done to find the best cutoff point for leukocyte counts in 
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relation to any complications. According to this analysis, a 
leukocyte count of 6750/mm³ with a sensitivity of 80.2% and 
a specificity of 56.4%, and a count of 7550/mm³ with a sen-
sitivity of 63.2% and a specificity of 74.6% indicated at least 
one diabetes complication. Our cutoff point of 7000/mm³ had 
a sensitivity of 73.3% and a specificity of 66.0% (area under 
the curve = 0.778, P , 0.0001), (Figure 1).
Leukocyte counts in 88 (47.8%) patients was lower than 
7000/mm³ and the other 96 (52.2%) had higher leukocyte 
counts. Out of all of our patients, 26 (14.3%) had cardio-
vascular complications; 64 (35.6%) had albuminuria and 65 
(35.9%) suffered from retinopathy. Only 13 (14.8%) of the 
88 evaluated patients with leukocyte counts under 7000/mm³ 
were diagnosed with retinopathy; but 53 (55.2%) out of the 
96 patients with leukocyte counts of more than our cutoff 
point had retinopathy (P , 0.001). Albuminuria was evident 
in 17 (19.3%) of the 88 individuals with low (,7000/mm³) 
leukocyte counts, but it was detected in only 47 (49.5%) of 
patients out of 96 with high leukocyte counts (P , 0.001).
Ischemic heart disease (IHD) was evaluated in only 100 
of the available patients; 26 had a positive history. Only six 
(12.2%) out of the 49 patients with low leukocyte counts 
were in this group, compared with 20 (39.2%) patients with 
high leukocyte counts and IHD (P = 0.02).
There was a statistically significant difference between 
mean age in the groups with low and high leukocyte counts 
(53.8 ± 11.4 versus 57.6 ± 10.4 years, respectively, P = 0.02); 
this difference was more significant between the diabetes 
detection periods in these two groups (P = 0.009). Because 
of this difference, we adjusted our data for age and duration 
of diabetes using logistic regression and found that this dif-
ference was significant only for diabetes duration (P , 0.001, 
R² = 0.326, odds ratio = 0.829).
There was no significant difference between gender, lipid 
profile, mean blood pressure, BMI, and smoking history in 
patients with low or high leukocyte count (P . 0.05).
Discussion
Investigations to find an inflammatory biomarker as an indicator 
of diabetes complications have been under consideration for 
some years. Numerous biomarkers have been investigated.11–15 
In our opinion, the leukocyte count test can be added to the 
diabetes control protocol as an early predictor beside that of a 
routine physical examination. Leukocyte count can reflect the 
inflammatory situation of the whole system. This study was per-
formed to discover whether leukocyte count is a suitable indica-
tor for development of any type 2 diabetes complications.
As the results of this study show, higher leukocyte counts 
were correlated with both macrovascular and microvascular 
diabetes complications; it is notable that retinopathy and 
cardiac events in the group with higher leukocyte levels were 
Table 1 Baseline characteristic of patients
Age (years) Diabetes duration  
(years)
Cholesterol  
(mmol/l)
Triglyceride  
(mmol/l)
HDL (mmol/l) LDL (mmol/l)
Total 53 ± 13 6.9 ± 6.4 206 ± 46 210 ± 119 40.4 ± 7.1 119 ± 30
Male
WBC , 7000/mm3 (n = 53) 54.8 ± 10.7 8.4 ± 4.1 208 ± 46 212 ± 117 41.1 ± 13.0 127 ± 33
WBC . 7000/mm3 (n = 67) 57.9 ± 115 11 ± 7.6 206 ± 36 219 ± 93 39.3 ± 9.2 116 ± 26
P 0.129 0.048 0.778 0.702 0.351 0.183
Female
WBC , 7000/mm3 (n = 35) 52.5 ± 12.4 8.1 ± 6.9 210 ± 45 218 ± 111 43.3 ± 13.2 116 ± 40
WBC . 7000/mm3 (n = 30) 57.0 ± 7.4 11.4 ± 8.4 220 ± 41 255 ± 124.5 41.1 ± 10.0 135 ± 21
P 0.088 0.094 0.373 0.215 0.483 0.192
P 0.02 0.009 0.835 0.322 0.191 0.815
Notes: Bolded P values are significant.
Abbreviations: HDl, high density lipoprotein; lDl, low density lipoprotein; WBC, white blood count.
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Figure 1 ROC analysis based on having at least one microvascular complication.
Abbreviation: ROC, receiver operating characteristic.
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three times more prevalent, and nephropathy prevalence was 
more than two times higher in the group with low leukocyte 
counts. In the present study, there was a relationship between 
age and diabetes duration to leukocyte count – it can be said 
that patients with higher leukocyte counts were older and 
had had diabetes for longer. But some other studies showed 
different results and demonstrated that age and diabetes 
duration did not have any significant difference in patients 
with high or low leukocyte counts.21,22 To investigate these 
counter results, a logistic regression was done to eliminate 
the influences of each other on these results.
One study showed that fibrinogen as a cardiovascular 
risk predictor was higher in patients with complications of 
type 2 diabetes.21 Another study supports this result; a rela-
tion between C-reactive protein and metabolic syndrome 
suggested that it could be a part of its criteria.22 Knowing 
that the physiopathology of metabolic syndrome and type 2 
diabetes has the same insulin resistance,23–25 it can be con-
cluded that inflammatory response can play an important role 
in the development of diabetes complications.
In a similar cross sectional study in 2004 by Tong et al 
on 3776 Chinese diabetic patients in Hong Kong, it was 
demonstrated that leukocyte counts in the normal range were 
independently related to both micro- and macrovascular 
complications consisting of retinopathy, nephropathy, and 
IHD.14 Furthermore, the study found that there was a direct 
relationship between leukocyte count and BMI, mean blood 
pressure, and lipid profile. Another study conducted in Turin 
University on 659 Italian patients showed that there was a 
relationship between leukocyte count and albuminuria.26 In 
another cross sectional study in 2005 by Chung et al on 1480 
patients in Taiwan, significant relationships between neutro-
phils, monocytes, and lymphocytes counts with nephropathy 
were found,27 and later in 2007, Tsai et al demonstrated a 
relationship between leukocyte count and IHD.28 Our results 
were similar to those findings. The basic conclusion from all 
of these studies is that a rise in leukocyte count, even within 
the normal range, can predict the severity of and the number 
of complications in patients with type 2 diabetes.
These findings, like other studies, demonstrated that 
inflammatory biomarkers such as higher leukocyte count 
are related to metabolic syndrome, cardiovascular diseases, 
and insulin resistance, and provide evidence for the thesis 
regarding the role of leukocytosis in microvascular and 
macrovascular complications of diabetes.
Nowadays, scientists believe that inflammatory factors 
play an important role in the pathogeneses of complications. 
Chronic inflammation induces development and progression 
of type 2 diabetes, implying that immunologic and 
inflammatory mechanisms can play a role in procession of the 
disease.29,30 Another theory is that a low insulin level in the 
blood stimulates neutrophil production in bone marrow.31,32 
However, some receptors were found in diabetic patients’ 
immune systems that induce inflammation in blood vessels.33 
Chronic inflammation responses in addition to other risk 
factors can help to progress diabetes complications by 
inducing massive endothelium injury and an increase in some 
mediators and oxidative stresses.33
In this study – as a cross sectional study – a cause-and-
effect relationship between leukocyte counts and chronic 
complications was not determined. Another limitation of 
this study was that acute viral infections including cyto-
megalovirus, herpes, or another infection that could not be 
recognized may have changed the result of leukocyte count 
as an inflammatory biomarker.
This study did not find any significant difference in BMI, 
lipid profile, and mean blood pressure between patients with 
low or high leukocyte counts, but as mentioned above some 
studies showed that these are related.22,24 As an important 
factor in metabolic syndrome, cardiovascular disease and 
insulin resistance20,21 it is recommended that more work is 
done to highlight these controversies.
Therefore, leukocyte count can be a cost-benefit labora-
tory test that can identify diabetic individuals at high risk for 
micro- and macrovascular complications and can be used to 
prevent such patients from the possibility of morbid crises.
Conclusion
An elevated leukocyte count, even within the normal range, 
is associated with chronic complications in type 2 diabetes. 
Accompanied by other markers, chronic inflammation that 
can be shown by this factor could be related to pathogenesis 
and the progression of these diabetes-related   complications. 
Thus, leukocyte count, as a complete blood count test 
could be considered as an appropriate clinical examination 
for early diagnosis and prevention of microvascular and 
macrovascular complications thus reducing morbidity and 
mortality from this disease.
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